Early Stem Cell Transplant Improves Lymphoma Survival
Treatment particularly effective if patients are in remission
FRIDAY, Dec. 21 (HealthDay News) -- For patients with angioimmunoblastic T-cell lymphoma, high-dose chemotherapy and autologous stem cell transplantation improve survival, particularly if patients are in remission at the time of treatment, according to the results of a study published online Dec. 10 in the Journal of Clinical Oncology.
Charalampia Kyriakou, M.D., from University College London in the United Kingdom, and colleagues reviewed data from 146 patients with angioimmunoblastic T-cell lymphoma who had undergone high-dose chemotherapy and autologous stem cell transplantation.
After a median follow-up of 31 months, the researchers found that 95 patients (65 percent) were still alive. Of the 51 patients who died, 42 died from disease progression and nine died from treatment-related toxicity. Overall survival was 59 percent and the cumulative incidence of relapse was estimated at 51 percent at 48 months. The major factor affecting outcome was disease status at transplant, and patients who received a transplant during the first complete remission had significantly better progression-free and overall survival.
"This study shows that high-dose therapy and autologous stem cell transplantation offers the possibility of long-term disease-free survival to patients with angioimmunoblastic T-cell lymphoma," Kyriakou and colleagues conclude. "Early transplantation is necessary to achieve optimal results."